ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease

@article{DiFonzo2007ATP13A2MM,
  title={ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease},
  author={Alessio Di Fonzo and Hsin Fen Chien and Mariana P Socal and Sabrina Giraudo and Cristina Tassorelli and Giovanni Iliceto and Giovanni Fabbrini and R. Marconi and Emiliana Fincati and Giovanni Abbruzzese and Paolo Marini and Ferdinando Squitieri and Martin W. I. M. Horstink and Pasquale Montagna and A. Dalla Libera and Fabrizio Stocchi and Stefano Goldwurm and Joaquim J. Ferreira and Giuseppe Meco and Emilia Martignoni and Leonardo Lopiano and Laura Bannach Jardim and Ben A. Oostra and Egberto Reis Barbosa and Vincenzo Bonifati},
  journal={Neurology},
  year={2007},
  volume={68},
  pages={1557 - 1562}
}
Objective: To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset <21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD). Methods: We studied 46 patients, mostly from Italy or Brazil, including 11 with juvenile parkinsonism and 35 with YOPD. Thirty-three cases were sporadic and 13 had positive family history compatible with autosomal recessive inheritance. Forty-two had only parkinsonian signs… 

Figures from this paper

Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
TLDR
This family, the third reported with homozygous PARK9 mutations and the first with mutations in two genes for atypical juvenile parkinsonism, illustrates that PARK9-linked disease might display wide intra-familial clinical variability and milder phenotypes, suggesting the existence of strong, still unknown, modifiers.
PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE
TLDR
A Japanese patient with KRS with a novel mutation who developed early onset parkinsonism, dementia, and other features is described and PET findings of PARK9 -linked parkinsonistan are described.
ATP13A2 variants in early‐onset Parkinson's disease patients and controls
TLDR
The data suggest that two mutated ATP13A2 alleles are not a common cause of PD, and heterozygous variants are present in a considerable number of patients, but are not significantly more frequent in patients compared to controls.
Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion
TLDR
The phenotypic spectrum associated with genetic variants in ATP13A2 that previously comprised Kufor-Rakeb syndrome, spastic paraplegia 78, and neuronal ceroid lipofuscinosis type 12 (CLN12), to also include juvenile-onset ALS, as supported by both genetic and functional data.
Mutations in the ATP13A2 Gene and Parkinsonism: A Preliminary Review
TLDR
It is proposed that a single pathway whereby ATP13A2 mutations may contribute to NCLs and Parkinsonism is proposed, and how studies of mutations in this gene may provide new insights into PD pathogenesis and identify potential therapeutic targets is highlighted.
Genetic analysis of the ATP1B4 gene in Chinese Han patients with Parkinson’s disease
TLDR
Extended analysis of 202 patients with PD and 400 gender, age, and ethnicity matched healthy controls showed no significant differences between patients and control subjects for genotypic and allelic distributions, suggesting the variant in the coding region of the ATP1B4 gene may play little or no role in the development of PD in Chinese Han population.
ATP13A2 variability in Taiwanese Parkinson's disease
  • C. Chen, Chih-Hsin Lin, Yih-Ru Wu
  • Biology
    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • 2011
TLDR
It is hypothesized that rare variants of ATP13A2 may contribute to PD susceptibility in Taiwan, and G1014S is mislocalized mainly in the intralysosomal space, which is coherent with the prediction of prohibiting N‐myristoylation and membrane association.
ATP13A2 variability in Parkinson disease
TLDR
Neither ATP13A2 genetic variability nor quantitative gene expression in brain appears to contribute to familial parkinsonism or nonfamilial PD.
Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to ATP13A2 Mutation
TLDR
The findings support that ATP13A2 mutations may be considered a genetic etiology of neuronal lipofuscinosis and animal models with these mutations develop neurodegenerative disorders with CLN pathology.
The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms
TLDR
A new understanding is provided of the role that ATP13A2 plays in the development of PD and a therapeutic target is identified that may ameliorate α‐synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson's disease.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease
TLDR
It is suggested that mutations in Parkin contribute to the common form of PD and that heterozygous mutations, especially those lying in exon 7, act as susceptibility alleles for late‐onset form of Parkinson disease.
Early-onset parkinsonism associated with PINK1 mutations
TLDR
PINK1 homozygous mutations are a relevant cause of disease among Italian sporadic patients with early-onset parkinsonism, and this study suggests that, at least in some patients, these mutations are disease causing, in combination with additional, still unknown factors.
Novel parkin mutations detected in patients with early‐onset Parkinson's disease
TLDR
The patients with parkin mutations showed significantly earlier onset, longer disease duration, more frequently symmetric onset, and slower disease progression than the patients without mutations, in agreement with previous studies.
How much phenotypic variation can be attributed to parkin genotype?
TLDR
Patients with mutations had significantly earlier and more symmetrical onset, dystonia more often at onset and hyperreflexia, slower progression of the disease, and a tendency toward a greater response to levodopa despite lower doses.
Diagnostic considerations in juvenile parkinsonism
TLDR
Patients in whom the clinical features of parkinsonism manifest before 21 years of age are described, suggesting that a juvenile form of idiopathic Parkinson's disease may be extremely rare.
Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?
TLDR
Long-term follow-up of a large family W provides an excellent opportunity to further evaluate the role of single heterozygous PINK1 mutations later in life, which will have major implications on genetic counseling.
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
TLDR
Loss-of-function mutations in a previously uncharacterized, predominantly neuronal P-type ATPase gene, ATP13A2, underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia are described.
Young onset Parkinson's disease
TLDR
It is believed that most, if not all, patients in this group have degenerative Lewy body idiopathic Parkinson's disease, representing the lower end of a skewed deviation for age of onset of this disease.
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
TLDR
The results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia
TLDR
Several new features were identified, including facial‐faucial‐finger mini‐myoclonus, visual hallucinations, and oculogyric dystonic spasms inKufor Rakeb disease, and a locus on chromosome 1p36 that was previously assigned PARK9 was identified.
...
...